News from the IMPAKT 2014 Breast Cancer Conference (8-10 May 2014, Brussels, Belgium).
Adoption of Multi-gene Assays in Hormone Receptor-Positive, HER2-Negative Breast Cancer
In a survey among physicians with at least 5 years of experience in treatment of breast cancer, a majority of respondents indicated that they would use multi-gene assays in clinical practice in a subset of patients with hormone receptor (HR)-positive, HER2-negative disease but they also cited several barriers.
Therapeutic Effect and Markers of Response of Palbociclib in HER2-Positive Breast Cancer Models
Tissue based markers are available to direct rational utilisation of selective CDK4/6 inhibitor palbociclib, according to the study performed in a combination of cell culture, mouse models, and human primary tumour explants.
Enzalutamide With or Without an Aromatase Inhibitor for Advanced Breast Cancer
In a first trial of enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer, pharmacokinetics and tolerability of enzalutamide have shown to be similar to that reported in men with metastatic castration-resistant prostate cancer.
Molecular Subtype of a Breast Cancer Relapse Influences Patient Post-Relapse Survival
Translational results from randomised phase III TEX trial show that breast cancer relapse characteristics display aggressive features with an over-representation of ER-negative, HER2-positive and highly proliferative tumours.
Combination of mTOR and AKT Inhibitors in Patients with Advanced Breast Cancer
A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206 showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence based on low RAS signature score.
No comments:
Post a Comment